Vanda Pharmaceuticals, Inc.
http://www.vandapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vanda Pharmaceuticals, Inc.
Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
Scholar Rock And Biohaven Get Ready To Flex Their Muscles In SMA
The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.
Bristol Gets Tumor-Agnostic Second Approval For Augtyro
Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.
Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid
Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice